Literature DB >> 19846991

Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer.

In Ja Park1, Gyu-Seog Choi, Soo Han Jun.   

Abstract

BACKGROUND: CA19-9 was evaluated as a prognostic marker for colorectal cancer and whether it could be helpful in addition to surveillance using CEA was also tested.
MATERIALS AND METHODS: Serum CA19-9 levels were measured preoperatively in 1109 patients and monitored at 3-month intervals for the first 2 years postoperatively, and at 6-month intervals thereafter in 700 patients.
RESULTS: Preoperative high CA19-9 was independent prognostic factor for recurrence. Among patients with recurrence, 21.4% had a high postoperative CA19-9. High postoperative CA 19-9 levels were more likely in patients with high preoperative levels. Postoperative CA19-9 increased more in patients with a peritoneal recurrence than in those with liver metastasis (p=0.002). Among patients with recurrence, CA19-9 increased in 7.8% of the patients with a normal follow-up CEA.
CONCLUSION: Postoperative CA19-9 was more frequently elevated when peritoneal recurrence occurred. Data on CA19-9 levels provided 7.8% of additional information in predicting recurrence in this study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19846991

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

1.  Treatment Outcome of Resection of Disseminated Peritoneal Metastases from Colorectal Cancer.

Authors:  Gaku Ohira; Hideaki Miyauchi; Koichi Hayano; Michihiro Maruyama; Shunsuke Imanishi; Toru Tochigi; Tetsuro Maruyama; Toshiharu Hanaoka; Koichiro Okada; Hisahiro Matsubara
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases.

Authors:  Xue-Qin Yang; Chuang Chen; Chun-Wei Peng; Shao-Ping Liu; Yan Li
Journal:  Med Oncol       Date:  2011-05-07       Impact factor: 3.064

3.  Role of blood tumor markers in predicting metastasis and local recurrence after curative resection of colon cancer.

Authors:  Yifan Peng; Zhiwei Zhai; Zhongmin Li; Lin Wang; Jin Gu
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer.

Authors:  Xue-Qin Yang; Yan Li; Chuang Chen; Chun-Wei Peng; Shao-ping Liu; Yang Liu
Journal:  Med Oncol       Date:  2010-04-07       Impact factor: 3.064

5.  Meprin α combined with CEA and CA19-9 improves prognostic prediction for surgically treated colorectal cancer patients.

Authors:  Hongfa Hou; Xinmin Gou; Juyuan Bu; Yonghui Su; Xinying Wei; Xiao Wang; Bingzong Hou
Journal:  Int J Clin Exp Pathol       Date:  2017-10-01

6.  Levels of CEA, CA153, CA199, CA724 and AFP in nipple discharge of breast cancer patients.

Authors:  Song Zhao; Yu Mei; Yongmei Wang; Jiang Zhu; Guixi Zheng; Rong Ma
Journal:  Int J Clin Exp Med       Date:  2015-11-15

7.  The clinical significance of preoperative serum levels of carbohydrate antigen 19-9 in colorectal cancer.

Authors:  Hyeon Yu; Gyung-Mo Son; Yong-Geul Joh
Journal:  J Korean Surg Soc       Date:  2013-03-26

8.  CA19-9 Concentration After First-line Chemotherapy Is Prognostic Predictor of Metastatic Colon Cancer.

Authors:  Ryosuke Hashizume; Hidejiro Kawahara; Masaichi Ogawa; Katsuhito Suwa; Ken Eto; Katsuhiko Yanaga
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

9.  Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review).

Authors:  Feng Jiao; Ziliang Jin; Lei Wang; Liwei Wang
Journal:  Biomed Rep       Date:  2013-08-20

10.  The survival after recurrence of colorectal cancer: a retrospective study focused on time to recurrence after curative resection.

Authors:  Hirotaka Furuke; Tomohiro Arita; Yoshiaki Kuriu; Hiroki Shimizu; Jun Kiuchi; Yusuke Yamamoto; Hirotaka Konishi; Ryo Morimura; Atsushi Shiozaki; Hisashi Ikoma; Takeshi Kubota; Masayoshi Nakanishi; Hitoshi Fujiwara; Kazuma Okamoto; Eigo Otsuji
Journal:  Surg Today       Date:  2021-07-16       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.